World's first biobank for recurrent head and neck cancer launches
NCT ID NCT05885490
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study creates a tissue bank and data registry for people with recurrent head and neck cancer. Researchers will collect samples and health information from thousands of participants to better understand the disease and find better treatments. The goal is to improve survival and set international standards for care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 10,000,000 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2050
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients undergoing treatment for histologically proven or suspected recurrent cancer of the head and neck
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged over 18 at time of diagnosis. * Confirmed clinical, radiological, and/ or histological diagnosis of residual, recurrent, or new primary malignant head and neck cancer arising from the nasopharynx, oropharynx, oral cavity, larynx, hypopharynx, sinonasal cavities, major salivary glands and thyroid gland. * Any mucosal, salivary gland, and thyroid histological subtype * Ability to give informed consent. * Details of clinical follow-up available For IReC-BIO only: * FFPE blocks(s) or fresh frozen tumour tissue available for collection * Two or more tumour-containing blocks available from the same specimen For QoL Questionnaires only: • Patients who have received a diagnosis of rHNC no earlier than 6 weeks prior to study entry Exclusion Criteria: • Recurrent cutaneous (e.g., SCC, melanoma), sarcomatous, and lymphatic or haematological (e.g. lymphoma) malignancies of the head and neck For IReC-BIO only: * FFPE tumour samples contain insufficient tumour sample for analysis. * Insufficient clinical details available For QoL Questionnaires only: • Patients who have received a diagnosis of rHNC more than 6 weeks prior to study entry
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Head cancer neck are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.